Enrollment completed in both Phase 3 chronic spontaneous urticaria global registration studies (EMBARQ-CSU 1 and 2) six months ahead of guidance; ...

Enrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSUTopline data ...

You probably know Jack Coyne by now. Maybe not by name, but you’ve seen him around, on TikTok, YouTube, or Instagram Reels.

A novel, non-hallucinogenic, experimental drug shows statistically significant, rapid, and durable improvement in PTSD symptom severity in a phase 2 trial.

Enrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSUTopline data expected Q4 2026BLA submission planned for 2027 HAMPTON, N.J., Feb. 25, 202 ...

Immunocore reports fourth quarter and full year 2025 financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q4 net sales of $104.5 million and $400.0 million for full year 2025; ...

Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BLA Submission Topline Safety, To ...

HDV (Hepatitis delta virus): A rare form of viral hepatitis requiring hepatitis B for replication and associated with severe ...

FDA Approval for Pediatric Indication -- LINZESS received U.S. FDA approval in November 2025 for IBS-C patients aged 7-17, ...

Dr Swanson tells families that almost all kids get poxvirus-caused bumps and while treatment isn’t mandatory, options include topical cantharidin, berdazimer gel, and intralesional candida injections.

Wildlife Expansion, Reintroduction Programs, and Changing Predator Behavior Create New Challenges for Rural Properties ...

Sarepta Therapeutics, Inc. ( SRPT) Q4 2025 Earnings Call February 25, 2026 4:30 PM EST ...